Search Results | Blood | American Society of Hematology

1-20 of 57

2 3

Sort by

Sort Order Select

Journal Articles

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Blood (2021) 138 (19): 1901–1905.

DOI: https://doi.org/10.1182/blood.2021012319

Published: 2021

Includes: Supplemental data

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

DOI: https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Andrew H. Wei, Massimo Breccia, Melissa Ooi, Maria Teresa Cedena Romero, Fabio Ciceri, Harry P. Erba, Anil Gaur, Romain Sechaud, Ensar Halilovic, Brigitte Kuenzle, Claire Fabre, Kimmo Porkka

Blood (2021) 138 (Supplement 1): 1283.

DOI: https://doi.org/10.1182/blood-2021-144650

Published: 2021

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

DOI: https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)

Blood (2021) 138 (Supplement 1): 1596.

DOI: https://doi.org/10.1182/blood-2021-145968

Published: 2021

Journal Articles

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Blood (2021) 138 (Supplement 1): 2607.

DOI: https://doi.org/10.1182/blood-2021-149147

Published: 2021

Journal Articles

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

María Diez-Campelo, Luis E. Benlloch, Emma Sasse, David Wormser, Leyla Hernandez Donoso, Silvia Colicino, Teresa Bernal, Antonieta Molero Yordi, Mar Tormo, Montserrat Arnan Sangerman, Guillermo Sanz, Marina Díaz-Beyá, María Teresa Cedena Romero, Andres Jerez, Brayan Merchán, David Valcárcel

Blood (2021) 138 (Supplement 1): 2605.

DOI: https://doi.org/10.1182/blood-2021-146019

Published: 2021

Journal Articles

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Blood (2021) 138 (Supplement 1): 544.

DOI: https://doi.org/10.1182/blood-2021-151557

Published: 2021

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

DOI: https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

Blood (2021) 138 (17): 1583–1589.

DOI: https://doi.org/10.1182/blood.2020009754

Published: 2021

Includes: Supplemental data

Journal Articles

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood (2021) 137 (1): 49–60.

DOI: https://doi.org/10.1182/blood.2020006731

Published: 2021

Includes: Supplemental data

Journal Articles

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-136258

Published: 2020

Journal Articles

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Bruno Paiva, PhD, María Belén Vidriales, Maria Desamparados Sampere Talens, Fabian Tarin, Enrique Colado, Celina Benavente, María Teresa Cedena, MD, Joaquin Sanchez, MD, Teresa Caballero-Velázquez, MD PhD, Lourdes Cordon, David Martínez-Cuadron, MD, Teresa Bernal del Castillo, MD PhD, Carmen Botella, Sofia Grille, MDPhD, Josefina Serrano, MD, Carlos Rodriguez, Jesús Lorenzo Algarra, Juan Manuel Alonso Dominguez, MD PhD MSc, Maria Luz Amigo, MD, Manuel BARRIOS García, MDPhD, Raimundo García-Boyero, MD, Mercedes Colorado, MD, Jaime Perez De Oteyza, MDPhD, Manuel Perez Encinas, MD, Lissette Del Pilar Costilla, MD, Maria Jose Sayas, Olga Pérez-López, Marcos González, Jose A. Perez-Simon, MD PhD, Joaquin Martinez-Lopez, MD PhD, Claudia Lucia Sossa, Alberto Orfao, MD PhD, Jesús F. San-Miguel, Miguel Sanz, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 13–15.

DOI: https://doi.org/10.1182/blood-2020-134349

Published: 2020

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

DOI: https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-136181

Published: 2020

Journal Articles

Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm) and Their Clinical Impact

María Poza, MD, Rafael Colmenares, MD, Alba González, Noemi Alvarez, Gonzalo Carreño Gomez-Tarragona, MD, Esther Onecha, PhD, María Teresa Cedena, MD, Pilar Martínez, MD, Juan Manuel de la Rosa, Inmaculada Rapado, PhD, Eva Barragán, PhD, Pau Montesinos, MD PhD, Rafael Llobet, Miguel Sanz, MD PhD, Joaquin Martinez-Lopez, MD PhD, Rosa Ayala, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-141534

Published: 2020

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

DOI: https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood (2020) 135 (26): 2375–2387.

DOI: https://doi.org/10.1182/blood.2019003382

Published: 2020

Includes: Supplemental data

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

DOI: https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 509.

DOI: https://doi.org/10.1182/blood-2019-128049

Published: 2019

2 3

NARROW

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma

Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm) and Their Clinical Impact

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only